**Chapter 6**

*Advances in Hematologic Malignancies*

England Journal of Medicine.

NEJMoa1605085

NEJMoa1509277

2014;**124**(21):5277

2016;**375**(11):1044-1053. DOI: 10.1056/

[140] Ofran Y, Izraeli S. BCR-ABL (Ph) like acute leukemia—Pathogenesis, diagnosis and therapeutic options. Blood Reviews. 2016;**31**:11-16. DOI:

10.1016/j.blre.2016.09.001

[135] Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: A historical

Therapeutics. 2012;**136**:334-342. DOI: 10.1016/j.pharmthera.2012.07.013

Thomas D, Sasaki K, Garcia-Manero G, Garris R, et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as front line therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL). Blood.

[137] Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's oncology group pilot study. Blood. 2008;**6**:3756- 3762. DOI: 10.1200/JCO.2007.15.3528

[138] Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and phase I clinical trial. Clinical Cancer Research. 2010;**16**(6):1894-1903. DOI: 10.1158/1078-0432.CCR-09-2980

[139] Park JH, Geyer MB, Brentjens RJ. CD19-targeted CART-cell therapeutics

Interpreting clinical outcomes to date. Blood. 2016;**127**(26):3312-3320. DOI: 10.1182/blood-2016-02-629063

for hematologic malignancies:

perspective. Pharmacology &

[136] Jabbour E, Kantarjian H,

[134] Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. The New England Journal of Medicine. 2016;**375**(8):740-753. DOI: 10.1056/

**98**
